GFAP and Alzheimer disease: GFAP immunoassays that target AD-specific GFAP isoforms and utilise different platforms, such as SIMOA, Nucleic Acid Linked Immuno-Sandwich Assay, SomaScan, Olink, and immunoprecipitation-mass spectrometry, can significantly increase the sensitivity and specificity of GFAP-based diagnostics in the future.